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Purposes: To assess whether the positive predictive value (PPV) of first-time rheumatoid 
arthritis (RA) diagnosis registration in the Danish National Patient Registry increases when 
data are linked to the RA treatment codes and to assess the PPV of first-time RA diagnoses 
according to RA serological subtypes.
Methods: Participants from the Danish Diet, Cancer, and Health cohort with at least one RA 
diagnosis, registered at one of the Central Denmark Region hospitals in the Danish National 
Patient Registry during the period 1977–2016, were identified. Register-based RA diagnoses 
were verified by scrutinizing medical records against RA classification criteria or clinical case 
RA. PPVs for overall RA, seropositive RA, and other RA were calculated for two models: first-
time RA diagnosis registration ever in the Danish National Patient Registry and first-time RA 
diagnosis registration ever where subsequently a prescription had been redeemed for a synthetic 
disease-modifying antirheumatic drug.
Results: Overall, 205 of 311 first-time register-based RA diagnoses were verified (PPV: 61.9%; 
95% CI: 56.9–67.0). Regarding RA serological subtypes, 93 of 150 register-based seropositive 
RA (PPV: 62.0; 95% CI: 53.9–69.5) and 36 of 144 other RA (PPV: 25.0; 95% CI: 18.5–32.8) 
were confirmed. When register-based RA diagnosis codes were linked to RA treatment codes, 
the PPVs increased substantially: the PPV for overall RA was 87.7% (95% CI: 82.5–91.5), 
the PPV for seropositive RA was 80.2% (95% CI: 71.6–86.7), and the PPV for other RA was 
41.1% (95% CI: 30.2–52.9).
Conclusion: The first-time RA diagnoses in the Danish National Patient Registry should be 
used with caution in epidemiology research. However, linking registry-based RA diagnoses to 
the subsequent RA treatment codes increases the probability of identifying true RA diagnoses, 
especially overall RA and seropositive RA.
Keywords: administrative database research, Danish National Prescription Registry, Anatomical 
Therapeutic Chemical codes, seropositive rheumatoid arthritis, Denmark
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease character-
ized by inflammation of synovial joints; it leads to irreversible joint damage, deformity, 
and functional impairment. Furthermore, RA patients are at higher risk of comorbidities 
and have a higher mortality rate than the general population.1,2
Large-scale registries have been widely used in research, contributing to knowledge 
regarding epidemiology, comorbidities, and mortality rates of RA patients.1–6
The Danish National Patient Registry is a Danish key health registry.7 It was 
established for administrative purposes in 1977 as an extension of county-based 
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hospital registration systems. For many decades, the  Danish 
National Patient Registry has been extensively used for 
epidemiological and clinical research. The registry contains 
comprehensive data regarding hospital contacts, including 
International Classification of Disease (ICD) codes.8 How-
ever, the validity of both in- and outpatient diagnostic data is 
open to discussion. Pedersen et al9 investigated the validity of 
217 RA diagnoses registered in the Danish National Patient 
Registry during the period 1977–2001. They found that the 
positive predictive value (PPV) of RA diagnoses was 59%. 
Ibfelt et al10 validated incident RA diagnoses recorded ≥2 
times within 90 days in rheumatology departments during 
2011. The PPV of RA diagnoses in their study was 79%. A 
study from the USA showed that the PPV of administrative 
registry-based RA diagnoses increased from 66% to 81% 
when data were linked to RA treatment codes.11
It is well known that seropositive and seronegative RA 
differ with respect to their phenotype, susceptibility genes, 
and the impact of smoking and obesity as risk factors.12–18 
Therefore, it is important to study these two serological 
subtypes separately.
The aims of our study were, first, to assess whether the 
PPV of first-time RA diagnosis registration in the Danish 
National Patient Registry increases when data are linked to 
the RA treatment codes and, second, to assess the PPV of 
first-time RA diagnoses according to serological subtypes.
Methods
setting
The study explored the PPV of RA diagnoses in the Dan-
ish National Patient Registry during the period 1977–2016 
among participants in the Danish Diet, Cancer, and Health 
cohort.19
Data sources
The Danish Diet, Cancer, and Health cohort study
The cohort was recruited during the period 1993–1997. 
Overall, 80,996 men and 79,729 women were invited, and a 
total of 57,053 accepted the invitation. The eligibility criteria 
were the following: age 50–64 years, born in Denmark, living 
in the Copenhagen or Aarhus counties, and no cancer diag-
nosis registered in the Danish Cancer Registry.20 A detailed 
description of the cohort has been published previously.19
All participants of the Danish Diet, Cancer, and Health 
cohort were linked to the Danish National Patient Registry7 
in February 2017 and subsequently linked to the Dan-
ish National Prescription Registry using the unique Civil 
 Personal  Registration number. This number is used in all 
 Danish registries, enabling data linkage at the individual 
level.
The Danish National Patient Registry
The registry contains data on all admissions to somatic 
hospitals since 1977 and on all visits to outpatient clinics 
since 1995,7 including hospital information, dates of hospital 
admissions, ward types, referral and discharge diagnoses, 
dates of each attendance at outpatient clinics, type of clinics, 
and diagnoses recorded at each attendance. The diagnoses 
were classified in accordance with the Danish version of the 
ICD-8 until the end of 1993 and thereafter in accordance 
with the updated version, ICD-10.8
The Danish National Prescription Registry
The Danish National Prescription Registry is a redemption 
database that was established in 1994.21 Every pharmacy in 
Denmark is equipped with an electronic accounting system 
to secure reimbursement from the National Health Service, 
which funds a variable proportion of the cost of prescribed 
medicine for every Danish citizen. Data are transferred to the 
Danish National Prescription Registry, which thus covers all 
reimbursed drugs at the level of the individual user.
The registry does not include information about drugs 
dispensed by hospital pharmacies directly to inpatients in 
relation to their hospital stays or to outpatients during their 
outpatient clinic attendances.
Validation of registry-based RA diagnoses
Identification of RA diagnoses
We included participants from the Danish Diet, Cancer, and 
Health cohort with at least one RA diagnosis, registered at 
one of the Central Denmark Region22 hospitals in the Dan-
ish National Patient Registry during the period 1977–2016.
The following ICD codes regarding RA diagnoses were 
retrieved from the Danish National Patient Registry: 712.39 
(arthritis rheumatoides alia et non specificata), M05 (seropos-
itive RA), and M06 (other RA) though not including M06.1 
(adult-onset Still disease). Only RA diagnoses registered as 
the main or the secondary diagnoses were included in the 
analyses, and referral diagnoses were not taken into account.
Verification of RA diagnoses
RA diagnoses identified in the Danish National Patient Reg-
istry were verified by scrutinizing medical records as follows: 
first-time RA diagnosis registrations were retrieved through 
the Danish National Patient Registry as described previously; 
then, relevant medical records from public hospitals and out-
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patient clinics were retrieved, and RA diagnoses were verified 
against the American College of Rheumatology (ACR) RA 
classification 1958 criteria,23 the ACR 1987 criteria,24 or the 
ACR/European League Against Rheumatism (ACR/EULAR) 
2010 criteria.25
If no RA classification criteria were met, verification was 
undertaken against clinical case RA. Clinical case RA was 
defined as arthritis where an assessment of RA was based 
on a rheumatologist’s expert opinion. If the RA diagnosis 
could not be confirmed, the likely alternative diagnosis was 
registered.
Register-based RA diagnoses with insufficient medical 
record information regarding satisfaction of the classifica-
tion criteria or clinical case RA definition were categorized 
as nonverified RA diagnoses.
Validation of registry-based RA diagnoses 
according to serological subtypes
Identification of RA diagnoses according to 
serological subtypes
Considering that only the ICD-10 diagnosis codes distinguish 
between serological subtypes of RA,8 verification of serologi-
cal subtypes was exclusively carried out among first-time 
ICD-10 code registrations.
Diagnoses registered with one of the “M05” codes as 
the first registration in the Danish National Patient Registry 
were defined as registry-based seropositive RA, and diag-
noses registered with one of “M06” codes were registered 
as other RA.
Only RA diagnoses registered as the main or the second-
ary diagnoses were included in the analyses, and referral 
diagnoses were not taken into account.
Patients with a previous ICD-8 RA code registration were 
not included in the analysis.
Verification of RA diagnoses according to serological 
subtypes
Register-based RA diagnoses were verified against the RA 
classification criteria or clinical case definition by review-
ing medical records, as described in the previous section. 
The criterion standard of RA seropositivity was defined as 
a positive blood test for IgM rheumatoid factor (RF) and/
or anti-citrullinated protein antibody (ACPA) before, at or 
within 1 month after the first-time registration in the Danish 
National Patient Registry. The criterion standard of other 
RA was defined as a negative blood test for IgM RF and, 
if an ACPA test had been undertaken, a negative blood test 
for ACPA before, at or within 1 month after the first-time 
registration in the Danish National Patient Registry.
Register-based RA diagnoses whose medical record 
information was insufficient in relation to satisfying the 
classification criteria, clinical case RA definition, or IgM 
RF/ACPA blood test results were categorized as nonverified 
RA diagnoses.
statistical analyses
Verification of the registry-based RA diagnoses
Every first-time RA diagnosis in the Danish National Patient 
Registry was classified as a true positive RA diagnosis or a 
nonverified RA diagnosis using the RA classification crite-
ria or clinical case definition based on medical records, as 
described earlier.
The PPV of registry-based RA diagnosis was estimated 
for two different models:
Model 1: first-time RA diagnosis registration ever in the 
Danish National Patient Registry;
Model 2: first-time RA diagnosis registration ever in the 
Danish National Patient Registry and where subsequently, 
at least once, a prescription had been redeemed for a syn-
thetic disease-modifying antirheumatic drug (sDMARD). 
Information about prescribed drugs was available only from 
1995. Therefore, subanalyses for RA diagnoses registered in 
the Danish National Patient Registry before and after 1995 
were carried out using the second model. The following 
Anatomical Therapeutic Chemical (ATC) codes26 from the 
Danish National Prescription Registry were retrieved: metho-
trexate (ATC: L01BA01, L04AX03), sulfasalazine (ATC: 
A07EC01), azathioprine (ATC: L04AX01), hydroxychloro-
quine (ATC: P01BA02), and leflunomide (ATC: L04AA13).
In Model 1, the PPV was determined as the fraction of 
true positive RA diagnoses among all first-time RA diagnoses 
recorded in the registry. In Model 2, the PPV was determined 
as the fraction of true positive RA among all first-time RA 
diagnoses recorded in the registry for cases, where subse-
quently at least once a prescription had been redeemed for a 
sDMARD. PPVs were presented with 95% CIs.
The PPV of RA diagnoses was subsequently explored 
according to patients’ gender, age group at the time of diag-
nosis (<50, 50–59, 60–69, >70 years), type of department 
(rheumatology, internal medicine, or other), type of patient 
(inpatient, outpatient, or other), type of RA diagnosis (main 
or secondary), calendar periods, based on the develop-
ment of RA classification criteria (1977–1987, 1988–2010, 
2011–2016),23–25 and ICD codes.8
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Verification of the registry-based RA diagnoses 
according to serological subtypes
Every first-time ICD-10 “M05” RA diagnosis in the Danish 
National Patient Registry was classified as a true positive 
seropositive RA or nonverified seropositive RA using the 
classification criteria or clinical case definition for RA and 
blood test results, as described earlier.
In the same manner, every first-time ICD-10 “M06” RA 
diagnosis in the registry was classified as a true positive other 
RA or nonverified other RA.
The PPVs of registry-based RA diagnoses, including 
serological subtypes, were estimated for two different models:
Model 1: first-time RA diagnosis registration ever in the 
Danish National Patient Registry with one of the ICD-10 
RA codes;
Model 2: first-time RA diagnosis registration ever in the 
Danish National Patient Registry with one of ICD-10 RA 
codes and where subsequently, at least once, a prescription 
had been redeemed for a sDMARD.
For seropositive RA in Model 1, the PPV was calculated 
as the fraction of true positive seropositive RA diagnoses 
among all first-time seropositive RA diagnoses (ICD-10 
“M05”) recorded in the Danish National Patient Registry. 
In Model 2, the PPV was ascertained as the fraction of true 
positive seropositive RA among all first-time seropositive 
RA diagnoses recorded in the registry and where subse-
quently, at least once, a prescription had been redeemed for 
a sDMARD.
The PPV of registry-based other RA diagnosis in Model 
1 was ascertained as the fraction of true positive other RA 
diagnoses among all first-time other RA diagnoses (ICD-10 
“M06”) recorded in the Danish National Patient Registry. 
In Model 2, the PPV was ascertained as the fraction of true 
positive other RA among all first-time other RA diagnoses 
recorded in the registry and, where subsequently, at least once, 
a prescription had been redeemed for a sDMARD.
Analyses were performed using Stata, version 14.2 
(StataCorp LP, College Station, TX, USA).
Results
A total of 331 participants in the Danish Diet, Cancer, and 
Health cohort were recorded as having RA at one of the 
Central Denmark Region hospitals in the period 1977–2016.
The characteristics of the registry-based RA diagnoses 
are presented in Table 1. As expected, the majority of persons 
recorded as having RA were women (70%). Most of the 
first-time RA diagnoses were recorded at a rheumatology or 
internal medicine department (78%) as the main diagnosis.
Verification of first-time RA diagnoses
For a total of 7% (23/331) of the diagnoses, no sufficient 
medical record information was available, and these diag-
noses were therefore defined as nonverified RA.
Table 1 Characteristics of first-time rheumatoid arthritis 
diagnoses recorded in the Danish National Patient Registry 
among participants in the Danish Diet, Cancer, and Health cohort 
and derived from the Central Denmark Region hospitals
Characteristics
Registered at least once with rheumatoid arthritis 
diagnosis during 1977–2016, n
331
Female, % (n) 70 (231)
Mean age, years (range) 65 (35–83)
Calendar periods, % (n)
1977–1987 6 (19)
1988–2010 70 (232)
2011–2016 24 (80)
Department type, % (n)
Rheumatology 58 (192)
internal medicine 20 (65)
surgery 16 (54)
Other 6 (20)
Patient type, % (n)
inpatient 40 (134)
Outpatient 57 (189)
Other 3 (8)
Diagnosis type, % (n)
Main (A-diagnosis) 78 (257)
Secondary (B-diagnosis) 22 (74)
ICD-8 codes, % (n) 11 (37)
ICD-10 codes, % (n)a 89 (294)
M05, % (n) 45 (150)
M06, % (n) 44 (144)
ICD codes by patients’ gender
Men, n 100
ICD-8 codes, % (n) 12 (12)
ICD-10 M05 codes, % (n) 49 (49)
ICD-10 M06 codes, % (n) 39 (39)
Women, n 231
ICD-8 codes, % (n) 11 (25)
ICD-10 M05 codes, % (n) 44 (101)
ICD-10 M06 codes, % (n) 45 (105)
ICD-10 codes by patients age at the time of 
rheumatoid arthritis diagnosis registration
M05, n 150
<50 years, % (n) 1 (2)
50–59 years, % (n) 22 (33)
60–69 years, % (n) 44 (65)
>70 years, % (n) 33 (50)
M06, n 144
<50 years, % (n) 1 (2)
50–59 years, % (n) 13 (19)
60–69 years, % (n) 46 (66)
>70 years, % (n) 40 (57)
Note: aICD-10 code M05 – seropositive rheumatoid arthritis, ICD-10 code M06 – 
other rheumatoid arthritis.
Abbreviation: ICD, International Classification of Diseases.
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Table 2 shows the PPVs of the first-time RA diagnoses 
registered in the Danish National Patient Registry. Using 
the Model 1 approach, RA diagnoses were confirmed for 
62% (205/331) of the registry-based diagnoses (95% CI: 
56.6–67.0). The majority of the confirmed diagnoses satisfied 
ACR or ACR/EULAR classification criteria (n=202), while 
others (n=3) met only the clinical case RA definition. ICD-8 
coded diagnoses had the highest PPV (PPV: 78%; 95% CI: 
61.5–89.2). Furthermore, a large proportion of the diagnoses 
was verified in the medical records if they were registered at 
a rheumatology department (PPV: 72%; 95% CI: 65.0–77.8), 
recorded as a main diagnosis (PPV: 68%; 95% CI: 62.1–73.5) 
or as a seropositive RA (PPV: 72%; 95% CI: 64.2–78.7).
When registry-based diagnosis codes were linked to 
the RA treatment codes in the Danish National Prescrip-
tion Registry (Model 2), the PPV of RA diagnosis was 
Table 2 The positive predictive values of first-time overall rheumatoid arthritis diagnoses recorded in the Danish National Patient 
Registry in the period 1977–2016 among the participants in the Danish Diet, Cancer, and Health cohort and derived from the Central 
Denmark Region hospitals
Characteristics Rheumatoid arthritisa Rheumatoid arthritis + sDMARDb
Confirmed  
rheumatoid 
arthritis, n
Registered 
rheumatoid 
arthritis, n
Positive 
predictive value 
% (95% CI)
Confirmed 
rheumatoid 
arthritis, n
Registered 
rheumatoid 
arthritis, n
Positive 
predictive value 
% (95% CI)
Overall 205 331 61.9 (56.6–67.0) 185 211 87.7 (82.5–91.5)
gender
Men 61 100 61.0 (51.0–70.2) 55 63 87.3 (76.2–93.7)
Women 144 231 62.3 (55.9–68.4) 130 148 87.8 (81.4–92.2)
agec (years)
<50 13 19 68.4 (42.8–86.3) 10 11 90.1 (46.3–99.2)
50–59 49 72 68.1 (56.2–78.0) 44 50 88.0 (75.2–94.7)
60–69 76 133 57.1 (48.5–65.4) 68 82 82.9 (73.0–89.7)
>70 67 107 62.6 (52.9–71.4) 63 68 92.7 (83.2–97.0)
Department type
Rheumatology 138 192 71.9 (65.0–77.8) 128 142 90.1 (84.0–94.1)
internal medicine 38 65 58.5 (45.9–70.0) 33 39 84.6 (68.9–93.2)
Other 29 74 39.2 (28.6–51.0) 24 30 80.0 (60.8–91.2)
Patient type
inpatient 86 134 64.2 (55.6–71.9) 77 84 91.7 (83.3–96.0)
Outpatient 115 189 60.9 (53.7–67.6) 104 123 84.6 (76.9–90.0)
Other 4 8 50.0 (14.3–85.7) 4 4 100
Diagnosis type
Main (A-diagnosis) 175 257 68.1 (62.1–73.5) 160 181 88.4 (82.8–92.3)
Secondary (B-diagnosis) 30 74 40.5 (29.8–52.3) 25 30 83.3 (64.3–93.3)
Calendar periods
1977–1987 13 19 68.4 (42.8–86.3) 10 12 83.3 (45.7–96.7)
1988–2010 144 232 62.1 (55.6–68.1) 131 149 87.9 (81.6–92.3)
2011–2016 48 80 60.0 (48.7–70.3) 44 50 88.0 (75.2–94.7)
ICD-8 codes 29 37 78.4 (61.5–89.2) 25 27 92.6 (72.8–98.3)
ICD-10 codesd
M05 108 150 72.0 (64.2–78.7) 102 111 92.0 (85.0–95.8)
M06 68 144 47.2 (39.1–55.5) 58 73 79.5 (68.4–87.4)
Notes: aPatients with first-time ever rheumatoid arthritis diagnosis registration in the Danish National Patient Registry; bpatients with first-time ever rheumatoid arthritis 
diagnosis registration in the Danish National Patient Registry who subsequently, at least once, redeemed a prescription for a sDMARD; cpatients’ age at the time of 
rheumatoid arthritis diagnosis registration; dICD-10 code M05 – seropositive rheumatoid arthritis, ICD-10 code M06 – other rheumatoid arthritis.
Abbreviations: ICD, International Classification of Diseases; sDMARD, synthetic disease-modifying antirheumatic drug.
 substantially higher (Table 2). Overall, 88% of RA diagnoses 
were confirmed (95% CI: 82.5–91.5). The PPV was higher 
for all categories compared with the PPV calculated using 
Model 1. The results were not different when stratified by 
periods (ie, before and after 1994 [establishment of the Dan-
ish National Prescription Registry], the PPV was 90% and 
87%, respectively).
Verification of first-time RA diagnoses 
according to serological subtypes
A total of 89% of the RA diagnoses (294/331) were registered 
with one of the ICD-10 RA codes, and these were almost 
equally distributed between “M05” (n=150) and “M06” 
(n=144) codes. Stratification by patient age at the diagnosis 
showed preponderance of seropositive RA diagnostic codes 
“M05” in younger patients (Table 1). Overall, for 8.7% 
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(13/150) of the “M05” and 25% (36/144) of the “M06” 
diagnoses, no sufficient medical record information was 
available, including IgM RF and/or ACPA test results, and 
these cases were thus defined as nonverified RA.
Table 3 shows the PPVs of first-time RA diagnoses 
according to serological status, registered in the Danish 
National Patient Registry with one of the ICD-10 RA codes. 
Using the Model 1 approach, 62% of registry-based, seroposi-
tive RA diagnoses were confirmed (95% CI: 53.9–69.5). The 
PPV of other RA diagnoses was 25% (95% CI: 18.5–32.8). 
Stratification by age group at the time of diagnosis registra-
tion revealed the highest PPVs in the youngest age group (<50 
years) for both seropositive (PPV: 100%) and other (PPV: 
50%) RA. However, there were only a few RA diagnosis 
registrations in both groups (Table 3). After linking the data 
to the RA treatment codes (Model 2), the PPV increased for 
both seropositive (PPV: 80%; 95% CI: 71.6–86.7) and other 
RA (PPV: 41%; 95% CI: 30.2–52.9) diagnoses. The highest 
PPV for seropositive RA diagnosis was in the youngest age 
group (PPV: 100%), while the highest PPV for other RA 
diagnosis was in the oldest age group (PPV: 60%; 95% CI: 
40.9–76.5) (Table 3).
Calculating the PPVs by gender showed that the PPVs for 
seropositive RA diagnoses were slightly higher for women 
than for men (using Model 1 – 63.4% vs 59.2%; Model 2 – 
81.6% vs 77.1%), whereas the PPVs for other RA diagnoses 
Table 3 Positive predictive values of first-time rheumatoid arthritis diagnoses according to serological subtypes registered in the 
Danish National Patient Registry in the period 1977–2016 among the participants in the Danish Diet, Cancer, and Health cohort and 
derived from the Central Denmark Region hospitals, overall and by age groups at the time of rheumatoid arthritis diagnosis
First-time diagnosis in the 
Danish National Patient 
Registry, ICD-10 codes
Rheumatoid arthritisa Rheumatoid arthritis + sDMARDb
Confirmed 
rheumatoid 
arthritis, n
Registered 
rheumatoid 
arthritis, n
Positive 
predictive value 
% (95% CI)
Confirmed 
rheumatoid 
arthritis, n
Registered 
rheumatoid 
arthritis, n
Positive 
predictive value 
% (95% CI)
M05 – seropositive rheumatoid 
arthritis
93 150 62.0 (53.9–69.5) 89 111 80.2 (71.6–86.7)
<50 yearsc 2 2 100d 2 2 100
50–59 yearsc 26 33 78.8 (60.6–90.0) 24 28 85.7 (66.0–94.9)
60–69 yearsc 34 65 52.3 (40.0–64.4) 33 43 76.7 (61.2–87.3)
>70 yearsc 31 50 62.0 (47.5–74.7) 30 38 79.0 (62.4–89.5)
M06 – other rheumatoid 
arthritis
36 144 25.0 (18.5–32.8) 30 73 41.1 (30.2–52.9)
<50 yearsc 1 2 50d 0 0 0
50–59 yearsc 1 19 5.3 (0.6–33.8) 0 6 0
60–69 yearsc 15 66 22.7 (14.0–34.7) 12 37 32.4 (18.9–49.7)
>70 yearsc 19 57 33.3 (22.1–46.9) 18 30 60.0 (40.9–76.5)
Notes: aPatients with the first-time ever rheumatoid arthritis diagnosis registration in the Danish National Patient Registry; bpatients with the first-time ever rheumatoid 
arthritis diagnosis registration in the Danish National Patient Registry who subsequently, at least once, redeemed a prescription for a sDMARD; cpatients’ age at the time of 
rheumatoid arthritis diagnosis registration. dStata did not provide 95% CI in this case.
Abbreviations: ICD, International Classification of Diseases; sDMARD, synthetic disease-modifying antirheumatic drug.
were higher for men than for women (using Model 1 – 28.2% 
vs 23.8%; Model 2 – 45.0% vs 39.6%) (Table 4).
Table 5 shows the PPVs calculated stratifying by calen-
dar periods. The PPVs for seropositive RA diagnoses were 
similar for both periods. Though, the PPVs for other RA 
diagnoses after 2010 were higher than in the period before 
(using Model 1 – 40.0% vs 18.2%; Model 2 – 73.9% vs 
26.0%).
Figure S1 and Tables S1 and S2 show available IgM RF 
and ACPA blood test results and their distribution among 
confirmed RA diagnoses. In almost 70% of verified RA 
diagnoses, ACPA test results were not available at the time 
of RA diagnosis registration.
The most likely other diagnosis among nonverified RA 
diagnoses was osteoarthritis. Table 6 shows the distribution 
of the most likely alternative diagnoses. Post hoc analyses 
were performed taking some of the most likely alternative 
diagnoses into account. The following additional criterion 
in determining RA cases was used: patients with their first 
RA diagnosis in the Danish National Patient Registry who 
had subsequently, at least once, redeemed a prescription 
for a sDMARD and who had no ICD code for psoriatic or 
enteropathic arthropathies (ICD-8: 696.0; ICD-10: M07), 
systemic connective tissue disorders (ICD-8: 446, 716, 734; 
ICD-10: M30–M35), inflammatory bowel diseases (ICD-8: 
563; ICD-10: K50–K51), or sarcoidosis (ICD-8: 135.99; 
 
C
lin
ic
al
 E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.5
3.
13
1.
89
 o
n 
17
-D
ec
-2
01
8
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1715
Positive predictive value of rheumatoid arthritis diagnoses and subtypes
Table 4 Positive predictive values of first-time rheumatoid arthritis diagnoses according to serological subtypes registered in the 
Danish National Patient Registry in the period 1977–2016 among the participants in the Danish Diet, Cancer, and Health cohort and 
derived from the Central Denmark Region hospitals by gender
First-time diagnosis in the 
Danish National Patient 
Registry, ICD-10 codes
Rheumatoid arthritisa Rheumatoid arthritis + sDMARDb
Confirmed 
rheumatoid 
arthritis, n
Registered 
rheumatoid 
arthritis, n
Positive 
predictive value 
% (95% CI)
Confirmed 
rheumatoid 
arthritis, n
Registered 
rheumatoid 
arthritis, n
Positive 
predictive value 
% (95% CI)
Men
M05 – seropositive 
rheumatoid arthritis
29 49 59.2 (44.6–72.3) 27 35 77.1 (59.5–88.6)
M06 – other rheumatoid 
arthritis
11 39 28.2 (15.9–44.9) 9 20 45.0 (23.8–68.2)
Women
M05 – seropositive 
rheumatoid arthritis
64 101 63.4 (53.4–72.3) 62 76 81.6 (71.0–88.9)
M06 – other rheumatoid 
arthritis
25 105 23.8 (16.5–33.0) 21 53 39.6 (27.1–53.7)
Notes: aPatients with the first-time ever rheumatoid arthritis diagnosis registration in the Danish National Patient Registry; bpatients with the first-time ever rheumatoid 
arthritis diagnosis registration in the Danish National Patient Registry who subsequently, at least once, redeemed a prescription for a sDMARD.
Abbreviations: ICD, International Classification of Diseases; sDMARD, synthetic disease-modifying antirheumatic drug.
Table 5 Positive predictive values of first-time rheumatoid arthritis diagnoses according to serological subtypes registered in the 
Danish National Patient Registry in the period 1977–2016 among the participants in the Danish Diet, Cancer, and Health cohort and 
derived from the Central Denmark Region hospitals by calendar periods
First-time diagnosis in the 
Danish National Patient 
Registry, ICD-10 codes
Rheumatoid arthritisa Rheumatoid arthritis + sDMARDb
Confirmed 
rheumatoid 
arthritis, n
Registered 
rheumatoid 
arthritis, n
Positive 
predictive value 
% (95% CI)
Confirmed 
rheumatoid 
arthritis, n
Registered 
rheumatoid 
arthritis, n
Positive 
predictive value 
% (95% CI)
M05 – seropositive 
rheumatoid arthritis
1988–2010 71 115 61.7 (52.4–70.3) 68 84 81.0 (70.9–88.1)
2011–2016 22 35 62.9 (45.1–77.7) 21 27 77.8 (57.0–90.2)
M06 – other rheumatoid 
arthritis
1988–2010 18 99 18.2 (11.7–27.2) 13 50 26.0 (15.4–40.3)
2011–2016 18 45 40.0 (26.4–55.4) 17 23 73.9 (50.9–88.6)
Notes: aPatients with the first-time ever rheumatoid arthritis diagnosis registration in the Danish National Patient Registry; bpatients with the first-time ever rheumatoid 
arthritis diagnosis registration in the Danish National Patient Registry who subsequently, at least once, redeemed a prescription for a sDMARD.
Abbreviations: ICD, International Classification of Diseases; sDMARD, synthetic disease-modifying antirheumatic drug.
ICD-10: D86) in the previous or following years in the Dan-
ish National Patient Registry. Using this additional criterion, 
96% of register-based overall RA diagnoses were confirmed 
(95% CI: 91.7–98.1); 85% of seropositive RA diagnoses 
(95% CI: 76.0–90.6) and 48% of other RA diagnoses (95% 
CI: 34.2–62.1) were confirmed.
Discussion
We found that, based on the ACR, ACR/EULAR classification 
criteria, or clinical case definition, only 62% of registry-based 
first-time RA diagnoses could be verified. Verification of RA 
diagnoses according to serological status was as low as 62% 
for seropositive RA and only 25% for other RA.
These findings are in line with those reported in previous 
Danish studies. Pedersen et al9 also validated RA diagnoses 
in the Danish National Patient Registry, using data from 
two large population-based cohorts. They identified 217 
RA diagnoses with available medical records registered at 
least once in the Danish National Patient Registry during 
1977–2001. A total of 59% of RA diagnoses were verified 
using the clinical case RA definition as a reference, and only 
46% of RA diagnoses were verified using the ACR 1987 
classification criteria as a reference. Another Danish study 
validated first-time RA diagnoses recorded in the Danish 
National Patient Registry during 2011.10 A total of 1,468 RA 
diagnoses were identified at a rheumatology department with 
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one of the ICD-10 codes M05.9, M06.0, M06.8, or M06.9, 
and having an additional visit due to RA within 90 days. They 
verified 79% register-based RA diagnoses, which is in line 
with our findings of 72% verified RA diagnoses registered 
at a rheumatology department.
We included all register-based RA diagnoses in the analy-
sis, even if medical records or IgM RF and ACPA blood test 
results were unavailable or inaccessible. Therefore, we esti-
mated the lowest possible PPVs within the study population.
Our findings of relatively low overall PPVs may have 
several explanations. First of all, referral RA diagnoses may 
be carried forward as tentative diagnoses until conclusive 
determination of diagnoses can be made. Second, physicians 
are expected to record as many relevant diagnoses as possible 
during daily clinical practice; however, no routine validation 
takes place, and self-reported arthritis may be registered as 
RA. We found that the most likely alternative diagnoses were 
osteoarthritis, polymyalgia rheumatica, crystal arthropathy, 
psoriatic arthritis, and connective tissue diseases, a finding 
that supports these misclassifications pitfalls. Finally, the reg-
istry may contain self-reported RA as a secondary diagnosis 
if patients were treated in private rheumatology clinics, and 
these are not captured by the Danish National Patient Regis-
try. Private practice medical records were not accessible for 
this study. It is, however, unlikely that this would have had a 
substantial impact on the overall results since the number of 
diagnoses with no sufficient medical records was low (7%).
In our study, register-based RA diagnoses were almost 
equally distributed among seropositive and other RA. Sev-
eral inception cohorts report that majority of RA patients 
are seropositive.27–29 The discrepancy may have several 
explanations. Our study showed that register-based other 
RA diagnoses are misclassif ied more frequently than 
seropositive RA diagnoses. Moreover, in our study, both 
register-based and confirmed other RA diagnoses were 
observed more frequently among older patients (>60 years) 
than younger patients (<60 years). Thus, the mean age at the 
time of RA diagnosis in our study was in favor of other RA. 
Furthermore, incident RA cohorts may not precisely reflect 
the real RA population due to their inclusion and exclusion 
criteria. Lower PPVs were estimated for the other RA codes 
than the seropositive RA codes. Given that RA is a slowly 
progressing disease with clinical similarities to other joint 
diseases, a tendency to record other RA rather than seroposi-
tive RA may appear if the RA diagnosis is uncertain. This 
misclassification may also be explained by physicians’ lack 
of awareness when selecting “M05” or “M06” RA codes in 
clinical practice.
The mean age at the time of RA diagnosis in our data 
was 65 years, which is higher than expected for the disease 
onset as indicated by inception cohorts.27,28 This may partly 
be attributed to the eligibility criteria for the Danish Diet, 
Cancer, and Health cohort.19 Furthermore, reduced functional 
status due to long-standing RA and concurrent comorbid 
conditions may have prevented potential attendees from 
participating in the Danish Diet, Cancer, and Health cohort.
We have observed that PPVs of other RA diagnoses 
registered during 2011–2016 were substantially higher than 
for diagnoses registered before 2011. It could partly be 
explained by availability of medical records, including IgM 
RF/ACPA test results.
PPVs increased substantially for both overall RA diag-
noses and serological subtypes when diagnoses were linked 
to RA treatment codes. This is in line with the findings of an 
American study of RA diagnosis validation.11 In that study, 
the PPV also increased substantially (from 66% to 81%) when 
the data were linked to RA treatment codes.
Our study has some limitations that merit discussion. 
First of all, we included RA diagnoses derived from only the 
Central Denmark Region hospitals, and therefore approxi-
mately 22% of the Danish population.22 Although the Dan-
ish health care system is uniformly organized throughout 
Table 6 The most likely alternative diagnoses among patients, 
first-time registered with rheumatoid arthritis diagnosis in the 
Danish National Patient Registry during 1977–2016, but not 
confirmed by reviewing medical records
Alternative diagnoses Number of 
nonconfirmed cases
Total number of nonconfirmed cases 106
Osteoarthritis 29% (n=31)
PMR or PMR with giant cell arteritis 9% (n=10)
Crystal arthropathy 9% (n=10)
Psoriatic arthritis 8% (n=9)
Connective tissue diseases 5% (n=5)
Tenosynovitis 3% (n=3)
Seronegative oligoarthritis 2% (n=2)
Enteropathic arthritis 1% (n=1)
Reactive arthritis 1% (n=1)
Juvenile idiopathic arthritis 1% (n=1)
rotator cuff syndrome 1% (n=1)
Subacromial bursitis 1% (n=1)
Dupuytren’s contracture 1% (n=1)
Arthralgia 1% (n=1)
Joint cyst 1% (n=1)
Myalgia 1% (n=1)
Unknown 26% (n=27)
Abbreviation: PMR, polymyalgia rheumatica.
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all regions, including the diagnosis registration procedure, 
regional differences may appear, and hospitals may vary in 
their registration practices, with higher PPVs anticipated for 
more accurate registrations.
Furthermore, the density of private rheumatology clin-
ics differs between the regions,30 and the PPVs would be 
expected to be lower in regions with a higher density of 
private practice rheumatologists due to inaccessibility to 
medical records. Still, our overall findings are in line with 
those reported by two previous Danish studies,9,10 suggest-
ing that such organizational differences had only a limited 
impact on the overall findings. It must, moreover, be taken 
into account that the structure of administrative registries 
differs between countries, and therefore our findings are not 
more broadly generalizable.
Unfortunately, we were unable to assess sensitivity, speci-
ficity, or negative predictive values due to the inaccessibility 
of medical records at private clinics. Furthermore, some RA 
patients may not seek medical advice, and thereby not be 
captured by any medical record or registry. These measures 
could have led to more precise assessment of the diagnostic 
accuracy of registry-based RA diagnoses.
Conclusion
Our findings show that data for first-time RA diagnoses 
in the Danish National Patient Registry must be used with 
caution due to misclassification. However, linking registry-
based RA diagnoses to the subsequent RA treatment codes 
increases the probability of identifying true RA diagnoses. 
The relatively high PPV of RA diagnosis registered with 
one of ICD-10 “M05” codes indicates a reliable means of 
coding seropositivity.
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Supplementary materials
Table S1 The blood test results of IgM RF and ACPA among confirmed ICD-10 M05 (seropositive) RA diagnoses in the Danish 
National Patient Registry in the period 1977–2016 among the participants in the Danish Diet, Cancer, and Health cohort and derived 
from the Central Denmark Region hospitals
Confirmed ICD-10 
M05 diagnoses, 
n=108
IgM RFa
aCPaa Positive, % (n) Negative, % (n) Not available, % (n) Overall, % (n)
Positive, % (n) 25 (27) 0 0 25 (27)
Negative, % (n) 4.6 (5) 0.9 (1) 0 5.6 (6)
Not available, % (n) 56.5 (61) 6.5 (7) 6.5 (7) 69.4 (75)
Overall, % (n) 86.1 (93) 7.4 (8) 6.5 (7) 100 (108)
Notes: aBlood test results before, at or within 1 month after the first-time registration in the Danish National Patient Registry.
Abbreviations: ACPA, anti-citrullinated protein antibody; ICD, International Classification of Diseases; IgM RF, immunoglobulin M rheumatoid factor; RA, rheumatoid 
arthritis.
Table S2 The blood test results of IgM RF and ACPA among confirmed ICD-10 M06 (other) RA diagnoses in the Danish National 
Patient Registry in the period 1977–2016 among the participants in the Danish Diet, Cancer, and Health cohort and derived from the 
Central Denmark Region hospitals
Confirmed ICD-10  
M06 diagnoses,  
n=68
IgM RFa
aCPaa Positive, % (n) Negative, % (n) Not available, % (n) Overall, % (n)
Positive, % (n) 2.9 (2) 1.4 (1) 0 4.3 (3)
Negative, % (n) (0) 26.5 (18) 0 26.5 (18)
Not available, % (n) 10.3 (7) 26.5 (18) 32.4 (22) 69.2 (47)
Overall, % (n) 13.2 (9) 54.4 (37) 32.4 (22) 100 (68)
Notes: aBlood test results before, at or within 1 month after the first-time registration in the Danish National Patient Registry.
Abbreviations: ACPA, anti-citrullinated protein antibody; ICD, International Classification of Diseases; IgM RF, immunoglobulin M rheumatoid factor; RA, rheumatoid 
arthritis.
Figure S1 Serological status among confirmed RA diagnoses with available blood test results on IgM RF and/or ACPA before, at or within 1 month after the first-time 
registration in the Danish National Patient Registry in the period 1977–2016 among the participants in the Danish Diet, Cancer, and Health cohort and derived from the 
Central Denmark Region hospitals.
Notes: aRegistered with the ICD-8 code “712.39” (Arthritis rheumatoides alia et non specificata) at their first registration in the Danish National Patient Registry. bregistered 
with one of ICD-10 “M05” (seropositive RA) codes at their first registration in the Danish National Patient Registry. cRegistered with one of ICD-10 “M06” (other RA) codes 
at their first registration in the Danish National Patient Registry.
Abbreviations: ACPA, anti-citrullinated protein antibody; ICD, International Classification of Diseases; IgM RF, immunoglobulin M rheumatoid factor; RA, rheumatoid 
arthritis.
Validated RA 
diagnoses, 
n=205
ICD-8 codes,a
n=29
Blood test
results
available, n=26
IgM RF positive,
92% (n=24)
IgM RF or ACPA
positive,
92% (n=93)
IgM RF and
ACPA negative,
78% (n=36)
Blood test
results
available, n=101
Blood test
results
available, n=46
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ICD-10 "M06"
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